Wednesday, 17 May 2017

New Research Explores on Global Cardiac Biomarker Pipeline Analysis

Global Cardiac Biomarker Pipeline Analysis is a new market research publication announced by Reportstack. Cardiac Biomarker are defined as a protein based traceable substances that are released into the blood when the heart is stressed or damaged. These biomarkers are then measured to diagnose cardiac ischemia and acute coronary syndromes (ACS), conditions which are associated with the insufficient blood flow to the heart. Cardiac biomarker are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, ACS among others. 
Growing prevalence of cardiovascular diseases, increasing geriatric population coupled with the subsequent increase in the burden of heart diseases across globeare the major factors that are augmenting the demand of cardiac biomarkers in the market. In addition, ongoing clinical trials for identification of novel cardiac biomarkers are also estimated to drive the growth of cardiac biomarker market. However, technical issues associated with the sample collection and storage are estimated to hinder the growth of the market. 
Complete report available @ Global Cardiac Biomarker Pipeline Analysis
Cardiac biomarker pipeline is studied in detail by segmenting the market on the basis of the pipeline analysis by product, by application and by location of testing. The major drugs in the cardiac biomarkers pipeline are BAG3 (Biouniversia), CAVARISK CVD (CAVADIS), Copeptin (Thermo Fisher Scientific), Heart Diagnostic Assay (Prevencio), Sentinel CVD (Gene News), SomaScan Cardiovascular Diseases (Somalogic), Mirisk VP Assessment (Aviir) and H-FABP. On the basis of the applications, market is segmented into Acute Coronary Syndrome, Atherosclerosis, Congestive Heart Failure, Myocardinal Infarction and others. Myocardinal Infection is estimated to account for major share in the market owing to its highest prevalence among cardiovascular diseases. Further on the basis of the location testing, cardiac biomarker market is classified into laboratory testing and point of care testing. Point of care testing is estimated to account for major share in the market owing to its wide applications in hospitals and clinics.
Further, Cardiac biomarker product pipeline is analysed on the basis of the geographical regions. North America, Asia Pacific, Europe and Rest of the World are estimated to be the major regions that are contributing significantly towards the growth of the market. North America is the leading region in the market owing to large number of R&D activities on cardiac biomarker and high prevalence of cardiovascular diseases in the region. 
Some of the prominent players of the cardiac biomarkers market are Abbott Laboratories, Alere, BD Bioscience, Beckman-Coulter, BG Medicines, Biocompare, Biomeriux, Bio-Rad Laboratories Inc., Cardiogenics Inc., Critical Diagnostics, Danaher Corporation, DiaDexus, Guangzhou Wondfo Biotech Co., Life Sign LLC, LSI Medience Corporation, Mitsubishi, Ortho Chemical, Radiometer Medical, Randox Laboratories, Response Biomedical, Roche Diagnostic, Siemens Healthcare, Thermo Scientific and so on.
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research


Post a Comment

Subscribe to Post Comments [Atom]

<< Home